Nancy Holekamp, MD
Show Description +
Nancy Holekamp, MD, assesses VIEW study data to investigate a possible link between anti-VEGF drug response and genetic profile. Although the VIEW trials evaluated both ranibizumab and aflibercept, Dr. Holekamp's data review combines the two drugs in order to understand a class effect vis-à-vis genotype.
Posted: 8/03/2016
Nancy Holekamp, MD
Nancy Holekamp, MD, assesses VIEW study data to investigate a possible link between anti-VEGF drug response and genetic profile. Although the VIEW trials evaluated both ranibizumab and aflibercept, Dr. Holekamp's data review combines the two drugs in order to understand a class effect vis-à-vis genotype.
Posted: 8/03/2016
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of ASRS: 2016.
Please log in to leave a comment.